Exiger CEO Testifies Before Congress on Pharmaceutical Supply Chain Risks

September 17, 2025

Article

WASHINGTON, DC. SEPTEMBER 17, 2025 – Exiger CEO Brandon Daniels testified before the U.S. Senate Special Committee on Aging for the “Prescription for Trouble: Drug Safety, Supply Chains, and the Risk to Aging Americans” hearing.

Daniels was invited by the committee, led by Chairman Rick Scott and Ranking Member Kirsten Gillibrand, to share what Exiger’s AI and proprietary analysis of U.S. pharmaceutical supply chains reveals about the nation’s dangerous dependence on foreign producers and the risks posed to vulnerable populations, including American seniors.

Leaders from the healthcare industry, academia, regulatory bodies, and advanced technology testified on the urgent need for stronger Food and Drug Administration oversight, including more rigorous testing and foreign inspection parity, as well as the importance of reshoring the production of essential medications here at home in America. The hearing focused on the growing concerns surrounding the quality and safety of foreign-manufactured generic drugs, and how overdependence on foreign pharmaceutical production, especially from Communist China and India, has created vulnerabilities in America’s drug supply chain and jeopardizes both national security and public health. The committee raised particular concern over the disproportionate impact that substandard generics have on older Americans, who rely heavily on these medications, according to the hearing recap.

It follows the release of Exiger’s investigative report, “A Bitter Pill: America’s Dangerous Dependence on China-Made Pharmaceuticals,” earlier this year. The findings of the report are the results of Exiger’s AI-powered risk assessment of 2,300+ companies, including drug manufacturers, packagers, labelers and suppliers, and 1,300+ active pharmaceutical ingredients. Exiger’s analytics revealed patterns of severe quality control issues, including contamination and falsified testing data, deep dependencies on foreign drug manufacturers and unethical international sourcing practices, including forced labor.

Testimony from Exiger CEO Brandon Daniels

In his testimony, Daniels called for transparency, resilience, and domestic investment to protect seniors and safeguard national security. With nearly three-quarters of essential medicines sourced from overseas—primarily China and India—he warned that the U.S. is overexposed to foreign risks that jeopardize senior health, taxpayer dollars, and military readiness.

Summary:

75% of essential U.S. medicines depend on overseas suppliers.
Contaminated, counterfeit, and substandard drugs threaten seniors’ health.
Foreign dependence creates national security leverage for adversaries.
Transparency gaps obscure risk across the pharmaceutical ecosystem.

Recommendations:

Diversify global and domestic supply sources.
Incentivize U.S.-based manufacturing of critical medicines and APIs.
Require full transparency across pharmaceutical supply chains.
Embed resilience in healthcare and defense strategies.
Harness AI-driven tools to detect hidden vulnerabilities.
Enforce forced labor laws like the UFLPA.

Read Brandon Daniels’ full testimony here.

About Exiger

Exiger is revolutionizing the way corporations, government agencies and banks navigate risk and compliance in their third-parties, supply chains and customers through its software and tech-enabled solutions. Exiger’s mission is to make the world a safer and more transparent place to succeed. Empowering its 550 customers across the globe, including 150 in the Fortune 500 and over 55 organizations across the Defense Industrial Base and government agencies, with award-winning AI technology, Exiger leads the way in ESG, cyber, financial crime, third-party and supply chain management and recently achieved FedRAMP® Moderate Authorization. Named one of Fast Company’s 2023 and 2024 ‘Brands That Matter’ and recipient of the Third Party Risk Association’s 2024 Innovator Award, Exiger’s work has been recognized by 50+ AI, RegTech and Supply Chain partner awards. Learn more at Exiger.com and follow Exiger on LinkedIn.

For more information, please contact:

Kody Gurfein
Chief Marketing Officer
1.914.393.0398
kgurfein@exiger.com